Genenta Science (Nasdaq: GNTA)

📍 Milan, Italy🗓 Founded 2014👥 23 employees💰 Last funded Sep 2020
Biotechnology Research🌐 genenta.com
Website LinkedIn
Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genentas first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2014
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Italy
3
Investor activity2015–2020 · investors recorded per year
2015120202
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Genenta Science (Nasdaq: GNTA)?
Genenta Science (Nasdaq: GNTA) has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did Genenta Science (Nasdaq: GNTA) last raise funding?
The most recent investment in Genenta Science (Nasdaq: GNTA) recorded on gritt.io was in September 2020.
When was Genenta Science (Nasdaq: GNTA) founded?
Genenta Science (Nasdaq: GNTA) was founded in 2014.
What industry is Genenta Science (Nasdaq: GNTA) in?
Genenta Science (Nasdaq: GNTA) operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Genenta Science (Nasdaq: GNTA) based?
Genenta Science (Nasdaq: GNTA) is headquartered in Milan, Italy.